Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? Academic Article Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Lymphoma, Non-Hodgkin

abstract

  • Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.

publication date

  • July 30, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1023/A:1016077907952

PubMed ID

  • 12164690

Additional Document Info

start page

  • 175

end page

  • 8

volume

  • 58

number

  • 2